lupus.bmj4d
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease
Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...
lupus.bmj5d
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...
lupus.bmj6d
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis
Objective Hydroxychloroquine (HCQ) is an antimalarial drug employed in the treatment of systemic lupus erythematosus (SLE). Prior studies reported inconsistent results regarding the association ...